Accéder au contenu
MilliporeSigma

Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning.

Biomedical engineering online (2014-08-21)
Min-Hua Chen, Po-Chin Liang, Kai-Chun Chang, Jian-Yuan Huang, Yu-Ting Chang, Fuh-Yu Chang, Jau-Min Wong, Feng-Huei Lin
RÉSUMÉ

The combination of biliary stent with photodynamic and chemotherapy seemed to be a beneficial palliative treatment of unresectable cholangiocarcinoma. However, by intravenous delivery to the target tumor the distribution of the drug had its limitations and caused serious side effect on non-target organs. Therefore, in this study, we are going to develop a localized eluting stent, named PDT-chemo stent, covered with gemcitabine (GEM) and hematoporphyrin (HP). The prototype of PDT-chemo stent was made through electrospinning and electrospraying dual-processes with an electrical charge to cover the stent with a drug-storing membrane from polymer liquid. The design of prototype used PU as the material of the backing layer, and PCL/PEG blends in different molar ratio of 9:1 and of 1:4 were used in two drug-storing layers with GEM and HP loaded respectively. The optical microscopy revealed that the backing layer was formed in fine fibers from electrospinning, while drug-storing layers, attributed to the droplets from electrospraying process. The covered membrane, the morphology of which was observed by scanning electron microscopy (SEM), covered the stent surface homogeneously without crack appearances. The GEM had almost 100% of electrosprayed efficiency than 70% HP loaded on the covered membrane due to the different solubility of drug in PEG/PCL blends. Drug release study confirmed the two-phased drug release pattern by regulating in different molar ratio of PEG/PCL blends polymer. The result proves that the PDT-chemo stent is composed of a first burst-releasing phase from HP and a later slow-releasing phase from GEM eluting. This two-phase of drug eluting stent may provide a new prospect of localized and controlled release treatment for cholangiocarcinoma disease.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tetrahydrofurane, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Tetrahydrofurane, contains 250 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
1,1,1,3,3,3-Hexafluoro-2-propanol, ≥99%
Sigma-Aldrich
Tetrahydrofurane, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
Tetrahydrofurane, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
Tetrahydrofurane, ReagentPlus®, ≥99.0%, contains 250 ppm BHT as inhibitor
Sigma-Aldrich
Tetrahydrofurane, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Tetrahydrofurane, ACS reagent, ≥99.0%, contains 250 ppm BHT as inhibitor
Supelco
1,1,1,3,3,3-Hexafluoro-2-propanol, for GC derivatization, LiChropur, ≥99.8%
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Supelco
Tetrahydrofurane, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Tetrahydrofurane, suitable for HPLC, ≥99.9%, inhibitor-free
Supelco
Tetrahydrofurane, analytical standard
Supelco
Tetrahydrofurane, Selectophore, ≥99.5%
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland